The European Medicines Agency (EMA) has adopted Implementing Regulation (EU) 2025/1466, amending Regulation 520/2012 and reinforcing the requirement for ongoing monitoring of EudraVigilance data. From 12 February 2026, Marketing Authorisation Holders (MAHs) in the EU/EEA must demonstrate that EVDAS outputs are fully integrated into their signal management process.
EVDAS, the EudraVigilance Data Analysis System, gives MAHs access to aggregated EU case data through electronic Reaction Monitoring Reports (eRMRs), line listings and ICSR forms. Under the new framework, what began as a pilot has now become a risk-based, auditable obligation. Inspectors will expect to see traceability and governance across detection, assessment and action, not just evidence that data were downloaded.
What the Change Means
To align with the new expectations, companies should:
- Define a product-specific EVDAS strategy within the Signal Detection Management Plan (SDMP).
- Establish risk-based review frequencies justified by lifecycle stage and risk profile.
- Synchronize EVDAS cycles with literature and safety database reviews.
- Maintain audit-ready documentation showing how signals move from detection to decision.
While GVP Module IX (Rev 1) remains in effect, an updated version is expected to further align with Regulation 2025/1466.
How EVERSANA Supports Compliance and Efficiency
We help sponsors operationalise EVDAS as part of a robust, inspection-ready signal management system through:
- Tailored SDMP design and tiered cadence planning.
- Automated scheduling and dashboards aligned with data-lock points.
- Integrated analytics pipelines linking EVDAS, literature, and safety database outputs.
- Clinician-led review and documentation ensuring regulatory consistency and scientific depth.
With implementation just months away, now is the time to assess SOPs, roles, and documentation for alignment with EMA expectations. We can help transform EVDAS monitoring from a compliance task into a strategic advantage, delivering quality, efficiency, and confidence across your signal lifecycle.
Author
Anita Yadav is the Global Aggregate Reports Lead at EVERSANA, with over 11 years of experience spanning pharmacovigilance, safety writing, and signal management across leading pharmaceutical companies and CROs. In her current role, she…